Q2 2021 Results - Reimagining Medicine

US Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References EntrestoⓇ grew 46% in Q2; confident in future growth based on 1L guideline position, label update and geographic expansion Sales evolution USD m, % cc Ex-US Weekly NBRx1 New-to-brand prescriptions 7.0k Strong momentum worldwide ■ US: sales grew +31% to USD 405m ■ Ex-US: sales up +63% to USD 481m +46% 6.5k 6.0k 886 5.5k 5.0k 580 481 4.5k 272 4.0k 3.5k 405 308 3.0k 2.5k Q2 2020 Q2 2021 See slide 55 for references. NBRX New-to-brand Prescriptions Inhibitor HFrEF - Heart Failure with reduced Ejection Fraction 21 Investor Relations | Q2 2021 Results 03/19 - 05/19 - 07/19 - 09/19 - 11/19- 01/20 - 11/20 - 01/21 - 03/21 - 05/21 - 07/21 - ■ China now 2nd biggest market, accounting for - one fourth of ex-US sales Confidence in future growth trajectory ■ ACC ECDP2 and draft ESC guidelines³ recommend ARNI first-line for all appropriate HFrEF patients, including de novo initiation ■ Label expansion strengthens essential role of EntrestoⓇ across HF continuum ■ China approval in essential hypertension ACC - American College of Cardiology ECDP - Expert Consensus Decision Pathway ESC European Society of Cardiology ARNI - Angiotensin Receptor Neprilysin HF Heart Failure All % growth relate to cc unless otherwise stated. ✓ NOVARTIS | Reimagining Medicine

View entire presentation